Immunotoxin therapy for hematologic malignancies: where are we heading?

Potala, 2008, Targeted therapy of cancer using diphtheria toxin-derived immunotoxins, Drug Discov. Today, 17–18, 807, 10.1016/j.drudis.2008.06.017 Choudhary, 2011, Therapeutic potential of anticancer immunotoxins, Drug Discov. Today, 11–12, 495, 10.1016/j.drudis.2011.04.003 Madhumathi, 2012, Therapeutic targets and recent advances in protein immunotoxins, Curr. Opin. Microbiol., 15, 300, 10.1016/j.mib.2012.05.006 Kreitman, 2006, Immunotoxins for targeted cancer therapy, AAPS J., 8, E532, 10.1208/aapsj080363 Schwemmlein, 2007, A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells, Leukemia, 21, 1405, 10.1038/sj.leu.2404687 Tsai, 2011, A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines, Toxins (Basel), 3, 409, 10.3390/toxins3040409 Herrera, 2009, A Phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia, J. Pediatr. Hematol. Oncol., 31, 936, 10.1097/MPH.0b013e3181bdf211 Schindler, 2011, A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia, Br. J. Haematol., 54, 471, 10.1111/j.1365-2141.2011.08762.x Barta, 2012, Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia, Leuk. Lymphoma, 10, 1999, 10.3109/10428194.2012.679267 Flavell, 2006, The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma, Br. J. Haematol., 134, 157, 10.1111/j.1365-2141.2006.06155.x Tobinai, 2003, Rituximab and other emerging monoclonal antibody therapies for lymphoma, Int. J. Clin. Oncol., 8, 212, 10.1007/s10147-003-0295-y Polito, 2004, The conjugate rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with fludarabine, Leukemia, 18, 1215, 10.1038/sj.leu.2403378 Kato, 2013, Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia, Leuk. Res., 37, 83, 10.1016/j.leukres.2012.09.010 Lechleider, 2011, Advances in the development of anti-CD22 immunotoxins containing pseudomonas exotoxin for treatment of hematologic malignancies, J. Cancer Sci. Ther., 3, 3, 10.4172/1948-5956.1000057 Kreitman, 2009, Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia, J. Clin. Oncol., 27, 2983, 10.1200/JCO.2008.20.2630 Kreitman, 2005, Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies, J. Clin. Oncol., 23, 6719, 10.1200/JCO.2005.11.437 Wayne, 2010, Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial, Clin. Cancer Res., 16, 1894, 10.1158/1078-0432.CCR-09-2980 Wayne, 2010, Complete remissions in 3 of 12 patients with pediatric acute lymphoblastic leukemia (ALL) during phase 1 testing of the anti-CD22 immunotoxin moxetumomab pasudotox, Blood ASH Annu. Meet. Abstr., 116, 3246 Kreitman, 2012, Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia, J. Clin. Oncol., 30, 1822, 10.1200/JCO.2011.38.1756 Onda, 2008, An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes, Proc. Natl. Acad. Sci. U. S. A., 105, 11311, 10.1073/pnas.0804851105 Bang, 2005, HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity, Clin. Cancer Res., 11, 1545, 10.1158/1078-0432.CCR-04-1939 Kawa, 2011, The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan, MAbs, 3, 479, 10.4161/mabs.3.5.17228 Onda, 2011, Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes, Proc. Natl. Acad. Sci. U. S. A., 108, 5742, 10.1073/pnas.1102746108 Liu, 2012, Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes, Proc. Natl. Acad. Sci. U. S. A., 109, 11782, 10.1073/pnas.1209292109 Mazor, 2014, Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes, Proc. Natl. Acad. Sci. U. S. A., 111, 8571, 10.1073/pnas.1405153111 Bera, 2014, An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies, Leuk. Res., 38, 1224, 10.1016/j.leukres.2014.06.014 Vallera, 2005, A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma, Clin. Cancer Res., 11, 3879, 10.1158/1078-0432.CCR-04-2290 Vallera, 2009, Genetic alteration of a bispecific ligand directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy, Leuk. Res., 33, 1233, 10.1016/j.leukres.2009.02.006 Tur, 2011, In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model, Int. J. Cancer, 129, 1277, 10.1002/ijc.25766 Hetzel, 2008, Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells, J. Immunother., 31, 370, 10.1097/CJI.0b013e31816a2d23 Stahnke, 2008, Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes, Mol. Cancer Ther., 7, 2924, 10.1158/1535-7163.MCT-08-0554 Mathew, 2009, Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy, Cancer Sci., 100, 1359, 10.1111/j.1349-7006.2009.01192.x Dean, 2010, Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies, J. Clin. Oncol., 28, 15 Borthakur, 2013, Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies, Haematologica, 98, 217, 10.3324/haematol.2012.071092 Schwemmlein, 2006, A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells, Br. J. Haematol., 133, 141, 10.1111/j.1365-2141.2005.05869.x Pastan, 2007, Immunotoxin treatment of cancer, Annu. Rev. Med., 58, 221, 10.1146/annurev.med.58.070605.115320 Bremer, 2006, CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia, Blood, 107, 2863, 10.1182/blood-2005-07-2929 Du, 2008, FCRL1 on chronic lymphocytic leukemia, Hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins, Blood, 111, 338, 10.1182/blood-2007-07-102350 Vallera, 2005, Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice, Leuk. Res., 29, 331, 10.1016/j.leukres.2004.08.006 Frankel, 2009, Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma, Curr. Drug Targets, 10, 104, 10.2174/138945009787354539 Shin, 2003, Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications, Cancer Immunol. Immunother., 52, 506, 10.1007/s00262-003-0374-y Polito, 2011, Immunotoxins and other conjugates containing saporin-s6 for cancer therapy, Toxins, 3, 697, 10.3390/toxins3060697 FitzGerald, 2011, Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates, Cancer Res., 71, 6300, 10.1158/0008-5472.CAN-11-1374 Kreitman, 2009, Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies, BioDrugs, 23, 1, 10.2165/00063030-200923010-00001 Potala, 2010, Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines – construction and characterization, J. Biotechnol., 148, 147, 10.1016/j.jbiotec.2010.04.006 Larson, 2012, Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia, Ocul. Immunol. Inflamm., 20, 312, 10.3109/09273948.2012.689071 Ohno, 2002, Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I, Leuk. Lymphoma, 4, 885, 10.1080/10428190290017042 Singh, 2012, Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy, Clin. Cancer Res., 18, 152, 10.1158/1078-0432.CCR-11-1839 Perentesis, 1997, Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias, Leuk. Lymphoma, 25, 247, 10.3109/10428199709114164 Kreitman, 1997, Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells, Blood, 90, 252, 10.1182/blood.V90.1.252 Kim, 1999, Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells, Leuk. Res., 23, 527, 10.1016/S0145-2126(99)00039-9 Antignani, 2005, A chimeric protein induces tumor cell apoptosis by delivering the human Bcl-2 family BH3-only protein Bad, Biochemistry, 44, 4074, 10.1021/bi0477687 Mathew, 2013, GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells, Apoptosis, 8, 882, 10.1007/s10495-013-0840-8 Vallera, 2003, Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene, Hum. Gene Ther., 14, 1787, 10.1089/104303403322611791 Frankel, 2008, Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia, Leuk. Lymphoma, 49, 543, 10.1080/10428190701799035 Du, 2007, New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells, J. Immunother., 30, 607, 10.1097/CJI.0b013e318053ed8e Potala, 2010, A novel fusion protein diphtheria toxin-stem cell factor (DT-SCF)-purification and characterization, Appl. Biochem. Biotechnol., 162, 1258, 10.1007/s12010-009-8896-1 Baskar, 2012, Targeting malignant B cells with an immunotoxin against ROR1, MAbs, 4, 349, 10.4161/mabs.19870 Baatar, 2007, CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors, J. Immunol., 179, 1996, 10.4049/jimmunol.179.3.1996